In a stride forward for treatment of Coronavirus patients the Drugs Controller General of India (DGCI) approved emergency use for Zydus Cadila’s Pegylated Interferon alpha-2b, ‘Virafin’ for treating moderate Covid-19 infection in adults.
Expert pulse is that single dose subcutaneous regimen of the antiviral drug will make treatment of COVID-19 disease more convenient.
On the other hand, Zydus Cadila on Friday announced that it has received restricted emergency use approval from the Drug Controller General of India (DCGI) to use antiviral drug Virafin for the treatment of moderate COVID-19 infections.
In the multicentre trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19. The drug has also shown efficacy against other viral infections,” the company said.
Masses are hopeful that this medicine proves beneficial in healing the Covid patients.